Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials

International Journal of Obesity

Volumn 26, Issue 2, 2002, Pages 262-273

  Haddock, C K ^a   Poston, W S C ^a   Dill, P L ^a   Foreyt, J P ^b   Ericsson, M ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Clinical trials; Meta analysis; Pharmacotherapy

Indexed keywords

AMFEPRAMONE; AMPHETAMINE; ANTIOBESITY AGENT; BENZOCAINE; BENZPHETAMINE; CAFFEINE; DEXAMPHETAMINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; LEVOTHYROXINE SODIUM; MAZINDOL; METFORMIN; METHAMPHETAMINE; METHAQUALONE; OBY TRIM; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENOBARBITAL; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PLACEBO; PRELU 2; SERTRALINE; SIBUTRAMINE; SLIM MINT; TETRAHYDROLIPSTATIN; TROCAINE; UNCLASSIFIED DRUG; X TROZINE;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HUMAN; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; OBESITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

MENTHA;

EID: 85047695511     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801889     Document Type: Article

References (145)

1. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: A criteria-based meta-analysis
2. Sibutramine and fat distribution: Is there a role for pharmacotherapy in abdominal/visceral fat reduction?
3. Clinical studies with phenylpropanolamine: A meta-analysis
4. Review of amphetamine like drugs by the Federal Drug Administration: Clinical data and value judgments
5. Phenylpropanolamine as an anorexiant agent weight control: A review of published and unpublished studies
6. Long-term weight loss: The effect of pharmacological agents
7. Long-term pharmacotherapy in the management of obesity
8. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
9. Sertraline and relapse prevention training following treatment by very-low-calorie diet: A controlled clinical trial
10. Effects of sibutramine on weight maintenance after weight loss: A randomized trial
11. Parametric measures of effect size
12. The efficacy of psychological, educational, and behavioral treatment: Confirmation from meta-analysis
13. Combining estimates of effect size
14. Estimation of effect size from a series of independent experiments
15. A power primer
16. Correlation and the coefficient of determination
17. Obesity as a medical problem
18. Phenylpronanolamine and the risk of hemorrhagic stroke
19. A risk-benefit assessment of anti-obesity drugs
20. Pharmacological treatment of obesity: Present status
21. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids
22. Pharmaceutical cost savings of treating obesity with weight loss medications
23. An evaluation of behavioral techniques reinforced with an anoretic drug in a double-blind weight loss study
24. Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women
25. A double-blind clinical trial of diethylpropion hydrochloride, mazindol, and placebo in the treatment of exogenous obesity
26. Three controlled trials of weight loss with phenylpropanolamine
27. Double-blind clinical evaluation of the anorectic activity of phenylpropanolamine hydrochloride drops and placebo drops in the treatment of exogenous obesity
28. Treatment of obesity: Comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial
29. A clinical trial of fenfluramine in obese children
30. A double-blind trial of mazindol using a very low calorie formula diet
31. Double blind clinical evaluation of mazindol (42-548) in obese diabetics
32. Diethylpropion hydrochloride: An effective appetite suppressant
33. The effects of phenylpropanolamine hydrochloride in overweight patients with controlled stable hypertension
34. A double-blind randomized placebo-controlled trial of sibutramine
35. The effect of long-term dexfenfluramine treatment on 24-hour energy expenditure in man: A double-blind placebo controlled study
36. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity: A double-blind multicentre trial in general practice
37. Effects of a combined behavioral and pharmacologic program on weight loss
38. A double-blind clinical trial of an appetite depressant, fenfluramine, in general practice
39. Effects of fenfluramine in hypertriglyceridemic obese subjects
40. A controlled trial of phentermine in obese diabetic patients
41. A study of fluoxetine in obese elderly patients with type 2 diabetes
42. Evaluation of Sanorex-a new appetite suppressant
43. Evaluation of Sanorex-a new appetite suppressant
44. Evaluation of Sanorex-a new appetite suppressant
45. Nonamphetamine, anorectic medication for obese diabetic patients: Controlled and open investigations of mazindol
46. Treatment of obesity: Cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs
47. Weight control and risk factor reduction in obese subjects treated for 2y with orlistat: A randomized controlled trial
48. Double-blind clinical evaluation of mazindol, dextroamphetamine and placebo in treatment of exogenous obesity
49. Double-blind comparison of placebo and 42-548, a new appetite suppressant, in obese volunteers
50. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
51. A collaborative investigation of fenfluramine: Anorexigenic with sedative properties
52. Controlled clinical evaluation of a new anorectic agent in obese adults
53. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity
54. Efficacy and safety of dexfenfluramine in obese patients: A multi-center study
55. Fluoxetine induced weight loss in overweight non-depressed humans
56. Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: Safety, efficacy, and additional benefit from dexfenfluramine
57. Prolonged action fenfluramine in nondiabetic patients with refractory obesity
58. Effects of caloric restriction and fenfluramine on weight loss and personality profiles of patients with long-standing obesity
59. Fluoxetine in obese patients with noninsulin-dependent diabetes mellitus
60. Pattern analysis method for assessing successful weight reduction
61. Fluoxetine: A randomized clinical trial in the treatment of obesity
62. A randomized double-blind clinical trial of fluoxetine in obese diabetics
63. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity
64. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity
65. International trial of long-term dexfenfluramine in obesity
66. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine
67. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study
68. A comparison of sibutramine and dexfenfluramine in the treatment of obesity
69. Double-blind trial of mazindol in overweight patients
70. Orlistat, a lipase-inhibitor, for weight maintenance after conventional dieting: A 1-y study
71. Body weight decreased in humans by phenylpropanolamine taken before meals
72. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance, and serum cholesterol in obese individuals
73. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
74. Comparison of fenfluramine (with ad libitum food intake) with 1000 calorie diet in obesity
75. Mazindol: Its efficacy and mode of action in generating weight loss
76. Thyroid as an adjuvant to amphetamine therapy of obesity: A controlled double-blind study
77. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients
78. Obesity-depression: Clinical evaluation with a new anorexigenic agent
79. Obesity-depression: Clinical evaluation with a new anorexigenic agent
80. Fluoxetine therapy in obese diabetic and glucose intolerant patients
81. Effect of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese patients: A double-blind placebo-controlled study
82. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity
83. Comparison of fenfluramine and metformin in the treatment of obesity
84. Use of a serotonin reuptake inhibitor, fluoxetine, in the treatment of obesity
85. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: A dose-response study
86. Treatment of obese patients with dexfenfluramine: A multicenter, placebo-controlled study
87. A placebo-controlled dose-response study of dexfenfluramine in the treatment of obese patients
88. Dexfenfluramine in the treatment of severe obesity: A placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake, and eating behavior
89. Dexfenfluramine influences dietary compliance and eating behavior, but dietary instruction may overrule its effect on food selection in obese subjects
90. Prolonged surveillance of dexfenfluramine in severe obesity
91. Long-term use of diethylpropion in obesity
92. Clinical assessment of the use of an anorectic drug in a total weight reduction program
93. Double-blind crossover evaluation of mazindol in the treatment of obese hypertensive patients
94. Treatment of refractory obesity with fenfluramine
95. A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity
96. A controlled study of a weight reduction regimen
97. Use of an anorexic drug in a total weight reduction program in private practice
98. Dexfenfluramine treatment of obesity: A double blind trial with post trial follow-up
99. Fluoxetine in the treatment of obese type 2 diabetic patients
100. A clinical pharmacologic study of benzphetamine (Didrex®), a new appetite suppressant
101. Treatment of obesity with fenfluramine
102. Metabolic effects of fenfluramine-a double-blind study
103. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity
104. Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet
105. A double blind trial of fenfluramine in the treatment of obesity
106. Effectiveness of phenylpropanolamine in the management of moderate obesity
107. A non-amphetamine anorectic agent: Preclinical background and a double-blind clinical trial
108. Effects of sibutramine on resting metabolic rate and weight loss in overweight women
109. A double-blinded, placebo-controlled, clinical study of the efficacy of a phenylpropanolamine/caffeine combination product as an aid to weight loss in adults
110. Mazindol in the treatment of obesity
111. The long-term management of obesity in general practice
112. A controlled clinical trial of benzphetamine (Didrex®) in the management of obesity
113. Some quantitative observations on a methampetamine-phenobarbital anorexic compound in obese outpatients
114. Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine
115. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
116. Effects of diet, exercise, and anorexigenic drugs on serum thryoid hormones
117. Double-blind trial of anorectic agents
118. Tenuate dospan as an appetite suppressant in the treatment of obese children
119. Dexfenfluramine in type II diabetes: Effect on weight and diabetes control
120. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: Effects on body composition, nutrient intake, and cardiovascular risk factors
121. A controlled trial of mazindol (Sanorex®, Teronao®) in the management of the obese rheumatic patients
122. Phentermine resin as an adjunct in medical weight reduction: A controlled, randomized, double-blind prospective study
123. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice
124. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month study dose-ranging study
125. Controlled comparative investigation of mazindol, d-amphetamine and placebo
126. The effect of fluoxetine on body weight, body composition and visceral fat accumulation
127. Fenfluramine in obese patients on various antihypertensive drugs: Double-blind controlled trial
128. A multicentre study comparing mazindol and placebo in obese patients
129. An 448 Sandoz (mazindol) in the treatment of obesity
130. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study
131. Long-term weight control study I (weeks 0 to 34): The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
132. Long-term weight control study II (weeks 34-104): An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise
133. Long-term weight control study III (weeks 104 to 156): An open-label study of dose adjustment of fenfluramine and phentermine
134. Long-term weight control study IV (weeks 156 to 190): The second double-blind phase
135. Long-term weight control study V (weeks 190 to 210): Follow-up of participants after cessation of medicine
136. Long-term weight control study VI: Individual participant response patterns
137. Long-term weight control study VI (weeks 0 to 210): Serum lipid changes
138. Long-term weight control study: Conclusions
139. Sibutramine in weight control: A dose-ranging, efficacy study
140. Clinical experience with a new dosage form of phentermine hydrochloride